Citations

Showing 10 of 108162 citations.

Neural Interfaces: An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite (Adv. Healthcare Mater. 23/2019)
Baumgart, Ian W. , Nicolai, Evan N. , Gosink, Brian A., Asp, Anders J., Polaconda, Shyam , Malerick, Kevin D., Brodnick, Sarah K. , McConico, Andrea L., Sanger, Zachary , Lee, Jannifer H. , Aho, Johnathon M. , Ross, Erika K., Lujan, Jose L., Williams, Justin C. , Franke, Manfred , Trevathan, James K. , Asp, Anders J., Settell, Megan L. , Zeng, Weifeng , Knudsen, Bruce E. , Suminski, Aaron J. , Ross, Erika K., Weber, Douglas J. , Ludwig, Kip A. , Shoffstall, Andrew J.

Mayo Clinic

Advanced Healthcare Materials | December 5, 2019 | Volume: 8 | Issue: 23 | Pages: No page available

10.1002/adhm.201970090 Get It

CpGtools: a python package for DNA methylation analysis
Wei, Ting , Nie, Jinfu, Larson, Nicholas B. , Ye, Zhenqing, Eckel‐Passow, Jeanette E. , Kocher, Jean‐Pierre , Wang, Liguo , Wang, Liguo , Larson, Nicholas B , Wei, Ting , Robertson, Keith D.

Mayo Clinic

Bioinformatics | December 5, 2019 | Volume: 37 | Issue: 11 | Pages: 1598-1599

10.1093/bioinformatics/btz916 | PMID 31808791 Get It

Abstract Motivation DNA methylation can be measured at the single CpG level using sodium bisulfite conversion of genomic DNA followed by sequencing or array hybridization. Many analytic tools have been developed, yet there is still a high demand for a comprehensive and multifaceted tool suite to analyze, annotate, QC and visualize the DNA methylation data. Results We developed the CpGtools package to analyze DNA methylation data generated from bisulfite sequencing or Illumina methylation arrays. The CpGtools package consists of three types of modules: (i) ‘CpG position modules’ focus on analyzing the genomic positions of CpGs, including associating other genomic and epigenomic features to a given list of CpGs and generating the DNA motif logo enriched in the genomic contexts of a given list of CpGs; (ii) ‘CpG signal modules’ are designed to analyze DNA methylation values, such as performing the PCA or t-SNE analyses, using Bayesian Gaussian mixture modeling to classify CpG sites into fully methylated, partially methylated and unmethylated groups, profiling the average DNA methylation level over user-specified genomics regions and generating the bean/violin plots and (iii) ‘differential CpG analysis modules’ focus on identifying differentially methylated CpGs between groups using different statistical methods including Fisher’s Exact Test, Student’s t-test, ANOVA, non-parametric tests, linear regression, logistic regression, beta-binomial regression and Bayesian estimation. Availability and implementation CpGtools is written in Python under the open-source GPL license. The source code and documentation are freely available at https://github.com/liguowang/cpgtools. Supplementary information Supplementary data are available at Bioinformatics online.
Fat Mass Index Better Identifies Metabolic Syndrome: Insights from Patients in Early Outpatient Cardiac Rehabilitation
Bonikowske, Amanda R. , Barillas-Lara, Maria Irene , Koepp, Katlyn E. , Medina‐Inojosa, José R. , Squires, Ray W. , Olson, Thomas P. , Medina-Inojosa, José R , Bonikowske, Amanda , López-Jiménez, Francisco

Mayo Clinic

Journal of Clinical Medicine | December 5, 2019 | Volume: 8 | Issue: 12 | Pages: 2147

10.3390/jcm8122147 | PMID 31817309 Get It

Body mass index (BMI) does not differentiate fat and lean mass or the distribution of adipose tissue. The purpose of this study was to examine the prevalence of metabolic syndrome (MetS) among patients entering outpatient cardiac rehabilitation (CR) across fat mass index (FMI) categories compared with BMI. This retrospective cross-sectional study evaluated dual-energy x-ray absorptiometry in 483 CR patients from 1 January 2014, through 31 December 2017. Clinical data were extracted from the electronic health record. Patients were grouped by FMI and BMI categories. Mean (SD) age of patients was 64.3 (14) years. The normal FMI category had 15 patients; excess fat, 74; and obese, 384. In contrast, 93, 174, and 216 were in the normal, overweight, and obese BMI categories, respectively. Prevalence of MetS was 0 (0%) in normal, 5 (1%) in excess fat, and 167 (54%) in obese FMI, with 97% in the obese category. MetS prevalence was 4 patients (0.8%) in normal, 39 (8%) in overweight, and 129 (27%) in obese BMI categories, with 75% of MetS in the obese category. FMI more accurately classified CR patients with metabolically abnormal fat (p < 0.001). FMI is a more sensitive index than BMI for metabolically abnormal fat of outpatient CR patients.
The Future of Care — Preserving the Patient–Physician Relationship
Noseworthy, John H., Noseworthy, John

Mayo Clinic

New England Journal of Medicine | December 4, 2019 | Volume: 381 | Issue: 23 | Pages: 2265-2269

10.1056/nejmsr1912662 | PMID 31800995 Get It

Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care
Navari, Rudolph M. , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita , Binder, G. , Coberly, Tammy Bratton, Schmerold, Luke, Roeland, Eric , Leblanc, Thomas , Roeland, Eric J , Potluri, Ravi C.

Mayo Clinic

JCO Oncology Practice | December 4, 2019 | Volume: 16 | Issue: 2 | Pages: e132-e138

10.1200/jop.19.00457 | PMID 31800352 Get It

PURPOSE: After ASCO and National Comprehensive Cancer Network guideline recommendations for triple antiemetic prophylaxis for carboplatin area under the curve (AUC) ≥ 4, and the publication of studies documenting avoidable acute care after chemotherapy involving nausea and vomiting (NV) and other toxicities, we studied clinician adherence to the guideline change and assessed avoidable acute-care use. METHODS: Using a large electronic health record database, we evaluated antiemetic prophylaxis as recommended in the guidelines and post-chemotherapy avoidable acute-care use (defined as involving any of NV or 8 other toxicities) for patients initiating carboplatin or other chemotherapy from October 2012 to August 2018. RESULTS: We identified 11,554 carboplatin courses. After the guideline change adding neurokinin-1 receptor antagonists (RAs) for carboplatin AUC ≥ 4, its use rose to 20% of courses from the prior average of 16%; virtually all courses also included a 5-HT3 RA plus dexamethasone. We found avoidable acute care in 23% of courses; one quarter of these events were associated with NV. Acute care rates after carboplatin mirrored those after other highly emetogenic chemotherapy or oxaliplatin and exceeded those after other chemotherapy regimens. The > 80% shortfall in adherence may have been caused by low awareness or acceptance of the guideline change and/or by poor awareness of avoidable acute-care use after carboplatin. CONCLUSION: Neurokinin-1 RA prophylaxis for carboplatin AUC ≥ 4 remains low and largely unchanged despite National Comprehensive Cancer Network and ASCO 2017 recommendations for inclusion. NV and avoidable acute care involving NV seen after carboplatin were consistent with other highly emetogenic chemotherapy. Clinician action is required to remediate incomplete prophylaxis and to no longer place patient outcomes, resources for cancer treatment, and clinician reimbursement at risk.
Risk Behaviors in Teens with Chronic Kidney Disease: A Study from the Midwest Pediatric Nephrology Consortium
Xiao, Nianzhou , Stolfi, Adrienne , Malatesta-Muncher, Rossana , Bholah, Reshma , Kogon, Amy J. , Eddington, Angelica R., Chand, Deepa H. , Greenbaum, Larry A. , Tran, Cheryl L. , Chishti, Aftab S. , Davis, Keefe, Matloff, Robyn , Woroniecki, Robert P. , Klosterman, Colleen, Luckritz, Kera E., Omoloja, Abiodun , Tran, Cheryl L , Chishti, Aftab , Omoloja, Abiodun , Hanevold, Coral Dawn

Mayo Clinic

International Journal of Nephrology | December 4, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-10

10.1155/2019/7828406 | PMID 31885919 Get It

Introduction . There is a paucity of information about risk behaviors in adolescents with chronic kidney disease (CKD). We designed this study to assess the prevalence of risk behaviors among teens with CKD in the United States and to investigate any associations between risk behavior and patient or disease characteristics. Methods . After informed consent, adolescents with CKD completed an anonymous, confidential, electronic web-based questionnaire to measure risk behaviors within five domains: sex, teen driving, alcohol and tobacco consumption, illicit drug use, and depression-related risk behavior. The reference group was composed of age-, gender-, and race-matched US high school students. Results . When compared with controls, teens with CKD showed significantly lower prevalence of risk behaviors, except for similar use of alcohol or illicit substances during sex (22.5% vs. 20.8%, p = 0.71 ), feeling depressed for ≥2 weeks (24.3% vs. 29.1%, p = 0.07 ), and suicide attempt resulting in injury needing medical attention (36.4% vs. 32.5%, p = 0.78 ). Furthermore, the CKD group had low risk perception of cigarettes (28%), alcohol (34%), marijuana (50%), and illicit prescription drug (28%). Use of two or more substances was significantly associated with depression and suicidal attempts ( p < 0.05 ) among teens with CKD. Conclusions . Teens with CKD showed significantly lower prevalence of risk behaviors than controls. Certain patient characteristics were associated with increased risk behaviors among the CKD group. These data are somewhat reassuring, but children with CKD still need routine assessment of and counselling about risk behaviors.
Ubrogepant for the Treatment of Migraine
Lu, Kaifeng , Finnegan, Michelle , Trugman, Joel M. , Szegedi, Armin, Dodick, David W. , Lipton, Richard B. , Ailani, Jessica

Mayo Clinic

New England Journal of Medicine | December 4, 2019 | Volume: 381 | Issue: 23 | Pages: 2230-2241

10.1056/nejmoa1813049 | PMID 31800988 Get It

Monozygotic twins discordant for congenital adrenal hyperplasia due to mosaicism
Kluge, Michelle L. , Graber, Evan , Foley, Kathryn C, Hansen, Lynnette V, Sellers, Heidi L , Milosevic, Dragana , Cradic, Kendall W, Grebe, Stefan K.

Mayo Clinic

European Journal of Endocrinology | December 4, 2019 | Volume: 182 | Issue: 2 | Pages: K7-K13

10.1530/eje-19-0249 | PMID 31804968 Get It

Introduction Genotype-phenotype discordance occurs occasionally in congenital adrenal hyperplasia (CAH). Its causes are largely unknown. We describe a case of monochorionic, diamniotic twins with discordant clinical presentations of CAH, and show evidence for this being due to mosaicism resulting from a postzygotic full gene deletion of CYP21A2 prior to twinning. Case description A 7-day-old 36-week gestation female infant (Twin A) presented to the emergency department with elevated 17-hydroxyprogesterone (17-OHP). Her identical twin (Twin B) had normal 17-OHP on newborn screening. Both twins showed signs of virilization, more pronounced in Twin B. Molecular genetic testing of both twins and their parents showed a WT paternally-inherited CYP21A2 and a maternally-inherited copy containing the c.293-13C>G mutation. Both twins were also found to have a 5′-CYP21A1P/CYP21A2-3′ hybrid (product of the common 30-kb deletion), derived from the deletion of the paternally-inherited CYP21A2. Neither mother nor father carried the deletion. Conclusions The genetic findings are consistent with mosaicism for two CYP21A2 cell lines in both twins. The first cell line is expected, based on parental results, while the second line is due to a postzygotic full gene deletion of the paternally-inherited WT CYP21A2. The resultant genotype, compound heterozygosity for c.293-13C>G and a CYP21A2 full gene deletion, is consistent with a salt-wasting CAH phenotype. Differential distribution of the second cell line between the twins is most likely the cause for their discrepant phenotypes. We believe this is the first report of somatic CYP21A2 mosaicism, and represents a novel cause for discrepant CAH phenotypes in monozygotic twins.